Rowlands S, Guillebaud J, Bounds W, Booth M
Contraception. 1983 Jan;27(1):39-49. doi: 10.1016/0010-7824(83)90054-9.
A postcoital contraceptive with a lower incidence of nausea and vomiting than oestrogen-progestogen combinations would be a significant advance. During a nine-month period, 101 women were treated at the Margaret Pyke Centre in London with either an oestrogen-progestogen combination or with danazol. A comparison of the side effects of each drug is reported. Those treated with danazol were six times less likely to experience nausea and none vomited. With the exception of breast symptoms, other side effects were five times less common in women receiving danazol. These differences give danazol a clear advantage in terms of patient acceptability. Further experience will enable the efficacy of danazol to be evaluated and so determine whether this drug should become the preferred hormonal postcoital treatment.
一种恶心和呕吐发生率低于雌激素 - 孕激素联合用药的性交后避孕药将是一项重大进展。在九个月的时间里,101名女性在伦敦的玛格丽特·派克中心接受了雌激素 - 孕激素联合用药或达那唑治疗。报告了每种药物副作用的比较情况。接受达那唑治疗的人出现恶心的可能性低六倍,且无人呕吐。除乳房症状外,接受达那唑治疗的女性出现其他副作用的情况要少五倍。就患者可接受性而言,这些差异使达那唑具有明显优势。进一步的经验将有助于评估达那唑的疗效,从而确定这种药物是否应成为首选的激素性交后治疗药物。